Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
NutraFuels, Inc. (NTFU) Makes Strides to Becoming Fully-Integrated in the Hemp-Derived CBD Sector, Forms Strategic Partnership with Maryland Based Botanical Products Processor - The Pharma Times | Pharma & Health Care News Portal

NutraFuels, Inc. (NTFU) Makes Strides to Becoming Fully-Integrated in the Hemp-Derived CBD Sector, Forms Strategic Partnership with Maryland Based Botanical Products Processor

Coconut Creek, November 25, 2018 : Through its wholly-owned subsidiary, Precision Analytic Testing, NutraFuels, Inc. (NTFU) has entered into an agreement with a Maryland based Botanical Products Processor to refine, distill and process Crude US Grown Hemp Oil into finished CBD-rich oil at its established Cambridge, MD facility.

The agreement will enable NTFU to offer and utilize cultivation, processing, and various forms of testing and procedures for bulk crude CBD oil into refined full-spectrum oil, distillate, and pure CBD in the form of isolate at the Processor’s Rural Maryland Council supported facilities. This Hemp Processor relationship will provide NTFU with a supply of finished CBD products and quality control of the processing of raw materials and finished CBD products in the hemp-CBD sector.

“We are pleased to announce this strategic alliance,” said Edgar Ward, CEO, and Founder of NutraFuels Inc. “This expansion ensures our supply as well as provides an additional revenue stream for NTFU as we strive to establish quality assurance and develop a gold standard in the hemp-derived CBD chain.”

NutraFuels, Inc is a fully reporting company in a class of securities registered with the U.S. Securities & Exchange Commission (SEC), Stock Symbol (OTCQB: NTFU). As reported in its Form 8-K filed with the SEC on November 13, 2018, NTFU recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

2 hours ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

1 week ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

2 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

2 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

2 weeks ago

HCG Cancer Centre Nagpur Launches Indigenous Scalp Cooling Therapy For Cancer Patients

Nagpur, April 03, 2024: HCG Cancer Center Nagpur has launched a one-of-a-kind indigenous Asia`s first…

4 weeks ago